Missouri Trust & Investment Co bought a new position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO – Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 56 shares of the medical research company’s stock, valued at approximately $29,000.
Several other hedge funds and other institutional investors also recently bought and sold shares of the business. Eads & Heald Wealth Management lifted its position in Thermo Fisher Scientific by 0.8% during the fourth quarter. Eads & Heald Wealth Management now owns 4,512 shares of the medical research company’s stock valued at $2,347,000 after purchasing an additional 37 shares during the period. Barlow Wealth Partners Inc. acquired a new position in shares of Thermo Fisher Scientific in the 4th quarter valued at about $210,000. XML Financial LLC grew its holdings in Thermo Fisher Scientific by 49.6% during the fourth quarter. XML Financial LLC now owns 863 shares of the medical research company’s stock worth $449,000 after acquiring an additional 286 shares during the period. Nisa Investment Advisors LLC lifted its holdings in Thermo Fisher Scientific by 4.8% in the fourth quarter. Nisa Investment Advisors LLC now owns 147,421 shares of the medical research company’s stock valued at $76,750,000 after acquiring an additional 6,713 shares during the period. Finally, Simon Quick Advisors LLC boosted its position in Thermo Fisher Scientific by 4.0% in the 4th quarter. Simon Quick Advisors LLC now owns 2,570 shares of the medical research company’s stock worth $1,337,000 after purchasing an additional 99 shares in the last quarter. Institutional investors and hedge funds own 89.23% of the company’s stock.
Analysts Set New Price Targets
Several equities analysts recently issued reports on the stock. Stephens began coverage on shares of Thermo Fisher Scientific in a research note on Tuesday, October 1st. They issued an “overweight” rating and a $680.00 target price for the company. Barclays dropped their target price on Thermo Fisher Scientific from $620.00 to $610.00 and set an “equal weight” rating on the stock in a research report on Wednesday, October 23rd. Scotiabank assumed coverage on Thermo Fisher Scientific in a research report on Monday, December 23rd. They set a “sector perform” rating and a $605.00 price target on the stock. TD Cowen boosted their price objective on Thermo Fisher Scientific from $656.00 to $686.00 in a research report on Tuesday, October 22nd. Finally, StockNews.com raised shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a research note on Tuesday, January 14th. Four analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $648.95.
Thermo Fisher Scientific Stock Up 2.4 %
Shares of NYSE:TMO opened at $572.85 on Wednesday. The company has a current ratio of 1.63, a quick ratio of 1.26 and a debt-to-equity ratio of 0.64. The company has a market capitalization of $219.11 billion, a price-to-earnings ratio of 35.92, a PEG ratio of 3.71 and a beta of 0.76. The business has a 50-day moving average price of $530.22 and a 200 day moving average price of $568.73. Thermo Fisher Scientific Inc. has a 12-month low of $493.30 and a 12-month high of $627.88.
Thermo Fisher Scientific (NYSE:TMO – Get Free Report) last posted its earnings results on Wednesday, October 23rd. The medical research company reported $5.28 earnings per share for the quarter, beating the consensus estimate of $5.25 by $0.03. Thermo Fisher Scientific had a net margin of 14.48% and a return on equity of 17.49%. The firm had revenue of $10.60 billion during the quarter, compared to the consensus estimate of $10.63 billion. During the same quarter last year, the firm earned $5.69 EPS. The firm’s revenue for the quarter was up .2% on a year-over-year basis. Sell-side analysts expect that Thermo Fisher Scientific Inc. will post 21.68 EPS for the current year.
Thermo Fisher Scientific Dividend Announcement
The company also recently announced a quarterly dividend, which was paid on Wednesday, January 15th. Shareholders of record on Friday, December 13th were given a $0.39 dividend. This represents a $1.56 annualized dividend and a yield of 0.27%. The ex-dividend date was Friday, December 13th. Thermo Fisher Scientific’s dividend payout ratio is currently 9.78%.
Thermo Fisher Scientific announced that its board has initiated a stock buyback program on Friday, November 15th that permits the company to buyback $4.00 billion in shares. This buyback authorization permits the medical research company to repurchase up to 2% of its shares through open market purchases. Shares buyback programs are generally an indication that the company’s management believes its shares are undervalued.
Insiders Place Their Bets
In other news, CEO Marc N. Casper sold 10,000 shares of the business’s stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $530.26, for a total transaction of $5,302,600.00. Following the completion of the transaction, the chief executive officer now directly owns 111,192 shares of the company’s stock, valued at approximately $58,960,669.92. The trade was a 8.25 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Gianluca Pettiti sold 300 shares of Thermo Fisher Scientific stock in a transaction that occurred on Friday, October 25th. The stock was sold at an average price of $560.16, for a total transaction of $168,048.00. Following the completion of the transaction, the executive vice president now owns 16,663 shares of the company’s stock, valued at $9,333,946.08. This represents a 1.77 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 47,150 shares of company stock worth $25,954,465 over the last three months. Company insiders own 0.34% of the company’s stock.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.
See Also
- Five stocks we like better than Thermo Fisher Scientific
- Stock Market Holidays 2022-2025 – Here’s When the NYSE and NASDAQ Will be Closed
- Ultrasound Weight Loss: GE HealthCare and Novo Nordisk’s Play
- How to Invest in the Best Canadian Stocks
- Super Micro Computer: Turning Risk Into Reward at the Crossroads
- Stock Market Upgrades: What Are They?
- After a Reset Year, Is Moderna Stock Poised for a Comeback?
Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO – Free Report).
Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.